491 related articles for article (PubMed ID: 32091413)
21. Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA.
Ritch E; Wyatt AW
Urol Oncol; 2018 Aug; 36(8):380-384. PubMed ID: 29248429
[TBL] [Abstract][Full Text] [Related]
22. Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer.
Peter MR; Bilenky M; Davies A; Isserlin R; Bader GD; Fleshner NE; Hirst M; Zoubeidi A; Bapat B
Sci Rep; 2021 Mar; 11(1):6630. PubMed ID: 33758253
[TBL] [Abstract][Full Text] [Related]
23. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
Bray AW; Duan R; Malalur P; Drusbosky LM; Gourdin TS; Hill EG; Lilly MB
Prostate; 2022 Sep; 82(13):1264-1272. PubMed ID: 35766303
[TBL] [Abstract][Full Text] [Related]
24. Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network.
Lee AR; Che N; Lovnicki JM; Dong X
Front Oncol; 2018; 8():93. PubMed ID: 29666783
[TBL] [Abstract][Full Text] [Related]
25. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.
Labrecque MP; Coleman IM; Brown LG; True LD; Kollath L; Lakely B; Nguyen HM; Yang YC; da Costa RMG; Kaipainen A; Coleman R; Higano CS; Yu EY; Cheng HH; Mostaghel EA; Montgomery B; Schweizer MT; Hsieh AC; Lin DW; Corey E; Nelson PS; Morrissey C
J Clin Invest; 2019 Jul; 129(10):4492-4505. PubMed ID: 31361600
[TBL] [Abstract][Full Text] [Related]
26. Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer.
Wang Z; Yan X; Tang P; Tang T; Wang Y; Peng S; Wang S; Lan W; Wang L; Zhang Y; Zhang J; Li K; Shu Z; Xu J; Qin J; Zhang D; Jiang J; Liu Q
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):180-187. PubMed ID: 36401126
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
[TBL] [Abstract][Full Text] [Related]
28. Tumor fraction in cell-free DNA as a biomarker in prostate cancer.
Choudhury AD; Werner L; Francini E; Wei XX; Ha G; Freeman SS; Rhoades J; Reed SC; Gydush G; Rotem D; Lo C; Taplin ME; Harshman LC; Zhang Z; O'Connor EP; Stover DG; Parsons HA; Getz G; Meyerson M; Love JC; Hahn WC; Adalsteinsson VA
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385733
[TBL] [Abstract][Full Text] [Related]
29. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.
Friedlander TW; Roy R; Tomlins SA; Ngo VT; Kobayashi Y; Azameera A; Rubin MA; Pienta KJ; Chinnaiyan A; Ittmann MM; Ryan CJ; Paris PL
Cancer Res; 2012 Feb; 72(3):616-25. PubMed ID: 22158653
[TBL] [Abstract][Full Text] [Related]
30. Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model.
Faugeroux V; Pailler E; Oulhen M; Deas O; Brulle-Soumare L; Hervieu C; Marty V; Alexandrova K; Andree KC; Stoecklein NH; Tramalloni D; Cairo S; NgoCamus M; Nicotra C; Terstappen LWMM; Manaresi N; Lapierre V; Fizazi K; Scoazec JY; Loriot Y; Judde JG; Farace F
Nat Commun; 2020 Apr; 11(1):1884. PubMed ID: 32313004
[TBL] [Abstract][Full Text] [Related]
31. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
Chen Z; Wu D; Thomas-Ahner JM; Lu C; Zhao P; Zhang Q; Geraghty C; Yan PS; Hankey W; Sunkel B; Cheng X; Antonarakis ES; Wang QE; Liu Z; Huang TH; Jin VX; Clinton SK; Luo J; Huang J; Wang Q
Proc Natl Acad Sci U S A; 2018 Jun; 115(26):6810-6815. PubMed ID: 29844167
[TBL] [Abstract][Full Text] [Related]
32. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.
Labrecque MP; Brown LG; Coleman IM; Lakely B; Brady NJ; Lee JK; Nguyen HM; Li D; Hanratty B; Haffner MC; Rickman DS; True LD; Lin DW; Lam HM; Alumkal JJ; Corey E; Nelson PS; Morrissey C
Cancer Res; 2021 Sep; 81(18):4736-4750. PubMed ID: 34312180
[TBL] [Abstract][Full Text] [Related]
33. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
Shafran JS; Andrieu GP; Györffy B; Denis GV
Mol Cancer Res; 2019 Aug; 17(8):1627-1638. PubMed ID: 31110158
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.
Karlsson A; Jönsson M; Lauss M; Brunnström H; Jönsson P; Borg Å; Jönsson G; Ringnér M; Planck M; Staaf J
Clin Cancer Res; 2014 Dec; 20(23):6127-40. PubMed ID: 25278450
[TBL] [Abstract][Full Text] [Related]
35. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
36. Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA).
Patsch K; Matasci N; Soundararajan A; Diaz P; Agus DB; Ruderman D; Gross ME
BMC Res Notes; 2019 May; 12(1):275. PubMed ID: 31092276
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide plasma DNA methylation features of metastatic prostate cancer.
Wu A; Cremaschi P; Wetterskog D; Conteduca V; Franceschini GM; Kleftogiannis D; Jayaram A; Sandhu S; Wong SQ; Benelli M; Salvi S; Gurioli G; Feber A; Pereira MB; Wingate AM; Gonzalez-Billalebeitia E; De Giorgi U; Demichelis F; Lise S; Attard G
J Clin Invest; 2020 Apr; 130(4):1991-2000. PubMed ID: 32149736
[TBL] [Abstract][Full Text] [Related]
38. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
39. Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer.
Mizuno K; Sumiyoshi T; Okegawa T; Terada N; Ishitoya S; Miyazaki Y; Kojima T; Katayama H; Fujimoto N; Hatakeyama S; Shiota M; Yoshimura K; Matsui Y; Narita S; Matsumoto H; Kurahashi R; Kanno H; Ito K; Kimura H; Kamiyama Y; Sunada T; Goto T; Kobayashi T; Yamada H; Tsuchiya N; Kamba T; Matsuyama H; Habuchi T; Eto M; Ohyama C; Ito A; Nishiyama H; Okuno H; Kamoto T; Fujimoto A; Ogawa O; Akamatsu S
Clin Cancer Res; 2021 Nov; 27(22):6164-6173. PubMed ID: 34526361
[TBL] [Abstract][Full Text] [Related]
40. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
